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 ABSTRACT 
Gamma-secretase is a membrane-bound aspartyl-protease that cleaves many membrane 
substrates including Amyloid Precursor Protein (APP), Notch, E-cadherin, Her4 and CD44. 
APP is a particularly notable substrate because of its association with Alzheimer disease. 
Together, gamma-secretase and beta-secretase cleave APP to produce amyloid beta peptides 
that aggregate in the brain as cytotoxic beta-amlyoid plaques, which is one of the hallmarks 
of Alzheimer disease. Many small molecules are being developed to target gamma-secretase 
as a therapeutic strategy for Alzheimer disease. However, studying the effects of these 
molecules on the active site conformation of gamma-secretase is challenging due to the 
complexity of this enzyme. In our study, we have developed new biochemical techniques to 
probe the active site structure of gamma-secretase. We are able to show that different 
gamma-secretase inhibitors and modulators, when bind to gamma-secretase, affect the active 
site structure of gamma-secretase differently. More importantly, we discovered that these 
small molecules, which were developed to target gamma-secretase, also affect the active site 
structure of Signal Peptide Peptidase, a similar membrane-bound aspartyl-protease. This 
discovery has major implication on the development of gamma-secretase inhibitors as 
therapeutic drugs for Alzheimer disease due to potential off-target effects. 
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